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Defining the structures and locations of the glycans attached on secreted proteins and virus
envelope proteins is important in understanding how glycosylation affects their biological
properties. Glycopeptide mass spectrometry (MS)-based analysis is a very powerful, emerging
approach to characterize glycoproteins, in which glycosylation sites and the corresponding
glycan structures are elucidated in a single MS experiment. However, to date there is not a
consensus regarding which mass spectrometric platform provides the best glycosylation
coverage information. Herein, we employ two of the most widely used MS approaches, online
high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC/
ESI-MS) and offline HPLC followed by matrix-assisted laser desorption/ionization mass
spectrometry (MALDI-MS), to determine which of the two approaches provides the best
glycosylation coverage information of a complex glycoprotein, the group M consensus HIV-1
envelope, CON-S gp140CFI, which has 31 potential glycosylation sites. Our results highlight
differences in the informational content obtained between the two methods such as the overall
number of glycosylation sites detected, the numbers of N-linked glycans present at each site,
and the type of confirmatory information obtained about the glycopeptide using MS/MS
experiments. The two approaches are quite complementary, both in their coverage of
glycopeptides and in the information they provide in MS/MS experiments. The information in
this study contributes to the field of mass spectrometry by demonstrating the strengths and
limitations of two widely used MS platforms in glycoprotein analysis. (J Am Soc Mass
Spectrom 2008, 19, 1209–1220) © 2008 American Society for Mass SpectrometryGlycoproteomics is a newly emerging field focus-ing on analysis of protein glycosylation. Thesestudies are important because glycosylation is
the most common post-translational modification
present in both eukaryotic and prokaryotic proteins [1,
2], and this modification effects proteins’ biological and
cellular processes and influences their physiochemical
properties [3–5]. Additionally, glycans have been
shown to play a vital role in various parasitic, bacterial,
and viral disease infections [6]. For instance, interaction
and fusion of the human immunodeficiency virus (HIV)
with its target host cells is mediated by its envelope
protein, gp160, which has over 50% of its mass com-
prising of glycans [7–10]. The high population and
diverse range of glycans on this protein acts as a shield
for the virus against the immune system; the glycans
also mask epitopes that impact HIV disease progression
[8, 11–17]. Consequently, conducting glycoproteomics
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doi:10.1016/j.jasms.2008.05.010studies on this target, defining the structures and loca-
tions of glycans in the HIV envelope protein, is impor-
tant in understanding how variation in glycosylation
affects the functions of this protein, and the studies may
also provide valuable information that can be useful in
identifying new vaccine candidates. To acquire this
information, sensitive, rapid, and reliable glycopro-
teomics methods for mapping and profiling protein
glycosylation are of paramount importance.
Analytical methods in the glycoproteomics field are
still evolving. Mass spectrometry (MS) has gained a
widespread use in protein glycosylation analysis and
has become an indispensable, powerful analytical tech-
nique in this research area. Analysis of protein glyco-
sylation by mass spectrometry is typically achieved by
two main approaches: The glycans can be released from
the peptide backbone either enzymatically or chemi-
cally, or the glycoprotein can be subjected to a protease
digestion, producing a mixture of peptides and glyco-
peptides. The latter approach is advantageous to releas-
ing glycans from the protein, since it does not require
extra sample manipulation and allows for site-specific
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obstacles encountered when using a glycopeptide-
based MS analysis. For example, glycopeptides exhibit
poor ionization efficiency and their signal is usually
suppressed by nonglycosylated peptides. In addition,
most glycosylation sites contain various glycoforms and
each glycoform may exist at low concentration in the
total glycopeptide mixture [19, 20]. To obviate these
obstacles, it is often necessary to perform an enrichment
or chromatographic separation before MS analysis. Sev-
eral studies have addressed this issue and proposed
effective enrichment or/and chromatographic methods
that can be utilized before MS analysis of glycopeptides
[3, 20].
Although glycopeptide-basedMS approaches are often
used for glycoprotein analysis, so far there is no consensus
as to which MS approach would provide the most glyco-
sylation information, especially for a complex glycopro-
tein. Recent advances in glycopeptide-based MS analysis
have been achieved by two emerging platforms, online
high performance liquid chromatography electrospray
ionization Fourier transform ion resonance (HPLC/ESI-
FTICR)-MS and offline HPLC/MALDI-TOF/TOF. These
methods are known for their unique high resolution and
high mass accuracy capabilities, along with their ability to
accommodate tandem mass spectrometry (MS/MS) ex-
periments. MALDI tandem time of flight (MALDI-TOF/
TOF) is widely used partly because it has a higher dy-
namic range and has a high tolerance to salts and other
contaminants. Besides, the complexity of data obtained in
ESI-FTICR-MS, due to the presence of multiply charged
ions and formation of salt adducts, greatly complicate
data interpretation of complex glycopeptide mixtures
[21]. However, unlike offline HPLC/MALDI-MS, online
HPLC-ESI-FTICR-MS is a powerful technique for analyz-
ing glycopeptidemixtures rapidly, efficiently, and in great
detail in a single experiment [22]. Furthermore, glycan-
specific ions can be selectively identified from full MS1
scans and used to trigger subsequent MSn scans during
chromatographic separation, thereby providing a plethora
of information about the glycopeptides in question [23].
On the contrary, MSn experiments cannot be performed in
MALDI-TOF/TOF, which limits the amount of informa-
tion that can be acquired using this platform. In addition,
MALDI analyses suffer frommatrix-dependent ionization
and fragmentation processes [24–27]. For instance, the
“hot” matrix, -cyano 4-hydroxycinnamic acid (CHCA),
commonly used with peptides and small neutral glycans,
is known to promote formation of glycosidic cleavages,
whereas 2,5-dihydroxybenzoic acid (DHB), a “cooler”
matrix that is typically used for glycopeptides and gly-
cans, is said to suppress MALDI-induced fragmentation
[24]. As a result, the type of matrix used for glycopeptide
analysis largely influences the extent and type of fragmen-
tation ions produced during MALDI-MS/MS experi-
ments [26]. Since neither of these two platforms stands out
as a clearly superior approach, we performed a head-to-
head comparison on both platforms, using a highly com-plex glycoprotein sample, to investigate the merits and
limitations of each method.
Herein, we present a detailed study to investigate the
merits of offline HPLC/MALDI-TOF/TOF and online
HPLC-ESI-FTICR when used to provide glycosylation
information of a recently characterized glycoprotein
containing 31 potential glycosylation sites [28]. Specifi-
cally, we employed the two platforms to analyze the
number of glycopeptides and the quality of MS data
obtained from the analysis of the glycoprotein, the
group M consensus HIV-1 envelope protein, CON-S
gp140CFI [29]. To ensure that the intrinsic worth of
each platform was fully exploited, we determined how
well each platform could answer several specific re-
search questions that will eventually contribute in un-
derstanding how glycosylation affects the function and
immunogenicity of the Env protein. These questions
included: How many of the 31 potential glycosylation
sites, if glycosylated, could be detected by each tech-
nique; what is the extent of glycosylation coverage
provided by each platform, for each glycosylation site;
what type of confirmatory information can be obtained
on both the peptide and glycan portions of the glyco-
peptides identified using collision induced dissociation
(CID) experiments. Our results revealed significant dif-
ferences in the glycosylation sites detected by using
each method, differences in the population of glyco-
forms identified and the type of structural information
obtained on either the peptide or glycan portion of the
identified glycopeptides. These results suggest that the
two techniques are highly complementary, and when
possible, the glycosylation information is maximized by
combining the two platforms.
Experimental
Materials and Reagents
PurifiedCON-S gp140CFI proteinwas produced as recom-
binant vaccinia virus expressed protein from Duke Human
Vaccine Research Institute in Durham, as described previ-
ously [29]. Urea, ethylenediaminetetraacetic acid (EDTA),
dithiothreitol (DTT), iodoacetamide (IAA), HPLC grade ace-
tonitrile (ACN), ammonium bicarbonate, trizma hydrochlo-
ride andbase, formic acid, 2,5-dihydroxybenzoic acid (DHB),
and -cyano-4-hydroxycinnamic acid (CHCA), were all pur-
chased from Sigma-Aldrich (St. Louis, MO). Proteomics
grade trypsin was obtained from Promega (Madison, WI).
N-Glycosidase F (PNGase F) fromElizabethkingia meningosep-
ticum was obtained from CalBioChem (San Diego, CA).
Water used for these studies was purified using a Millipore
Direct-Q3 Water Purification System (Billerica, MA).
Trypsin Digestion of CON-S gp140CFI Protein
Approximately 300 g of protein (about 2 nmol) was
prepared in 100 mM Tris-HCl buffer, containing 6 M
urea and 3 mM EDTA, pH 7.5. The protein was reduced
for 1 h with 15 mM DTT and alkylated for another hour
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amount of IAA was neutralized by adding DTT to a
final concentration of 40 mM. Extra buffer solution was
added to reduce the concentration of Urea. Trypsin was
added at a protein:enzyme ratio of 30:1 (wt/wt) to
generate glycopeptides. The protein solution was incu-
bated overnight at 37 °C. The reaction was quenched
the following day by adding 1 L of concentrated acetic
acid. The final protein concentration was10 pmol/L.
Two aliquots were removed from the total digest and
each aliquot was subjected to either online HPLC/ESI-
FTICR or offline HPLC fractionation before MALDI-
TOF/TOF MS. For each HPLC injection, a protein
solution of 1.4 g/L was utilized.
Reverse Phase HPLC Fractionation
The tryptic glycopeptides/peptides mixture was puri-
fied and separated on a Shimadzu model HPLC system
(Shimadzu, Columbia, MD). For each run, 20 L of the
tryptic digest was injected onto a C18 column (150 4.6
mm, 5 M; Alltech, Deerfield, IL) at a flow rate of 1
mL/min. Purified water and HPLC grade ACN each
containing 0.1% formic acid were used as mobile phase
A and B, respectively, with a linear gradient from 5% to
40% B over 50 min, followed by a ramp to 95% B in 10
min [30]. Fractions were manually collected every 1 min
for 60 min. Each fraction was evaporated to dryness on
a CentriVap (Labconco Corporation, Kansas City, MO)
before reconstituting with 10 L of water. The reconsti-
tuted fractions were first screened and analyzed by
MALDI-TOF/TOF and all fractions containing glyco-
peptides were then deglycosylated and reanalyzed by
MALDI-TOF/TOF MS.
Deglycosylation
Reconstituted HPLC glycopeptide fractions were enzy-
matically deglycosylated using PNGase F (CalBioChem)
by applying the protocol recommended by the manufac-
turer. Briefly, each enriched glycopeptide fraction was
deglycosylated by adding 4 L of 500 units/mL of
PNGase F and 25 L of 20 mM NH4HCO3 (pH  8), and
then incubated overnight at 37 °C. The reaction was
stopped by boiling and analyzed by MALDI-MS.
MALDI-TOF/TOF MS Analysis
Equal volumes of saturated solutions of DHB and
CHCA matrixes prepared in 50% ACN with 0.1% TFA
were used and mixed with each sample (1:1 by volume).
Approximately 0.75 L of the mixture was spotted on a
stainless steel MALDI target plate (Applied Biosystems,
Foster City, CA) and air-dried. All MALDI MS and
MS/MS data were acquired in the positive reflectron
ion mode on an Applied Biosystems 4700 proteomics
analyzer mass spectrometer. The samples were irradi-
ated by a 355 nm Nd-YAG laser (355 nm) at 200 Hz. The
acceleration voltage was 25 kV. Each mass spectrumwas generated by averaging 3200 laser shots. The laser
intensity was optimized to give the best signal-to-noise
ratio and resolution for each sample. All the data were
processed in Data Explorer version 4.5 (Applied Biosys-
tems). Glycopeptide analysis was performed by using
the high resolution MALDI-TOF/TOF MS in conjunc-
tion with our previously described web-based tool
(GlycoPep DB), [31] to assign glycopeptide composi-
tions. The assigned compositions were then confirmed
by using MALDI-MS/MS experiments.
Capillary HPLC/ESI- FTICR MS Analysis
Analysis of the tryptic glycopeptides on HPLC/ESI-
FTICR-MS was performed by using a Dionex Ultimate
capillary HPLC system (Sunnyvale, CA) equipped with
a Famous well plate autosampler coupled to a high
resolution Thermo Finnigan (San Jose, CA) linear ion
trap-Fourier transform ion cyclotron resonance (LTQ-
FTICR) mass spectrometer equipped with a 7 telsa
actively shielded magnet. Samples were loaded onto a
Famous well plate autosampler and 5 L of the tryptic
digest was injected onto an LC Packings C18 PeMap 300
column (LC Packings, Sunnyvale, CA) (300 m i.d. 15
cm, 5 m, 300 Å). Water and HPLC grade ACN each
containing 0.06% formic acid were used as mobile
phase A and B, respectively, with a linear gradient
starting from 5% to 40% B over 50 min, followed by a
ramp to 95% B in 10 min. The eluting solution was
directly infused into the mass spectrometer at a flow
rate of 5 L/min.
High resolution data were acquired on FTICR MS by
maintaining resolution at 50,000 for m/z 400. The instru-
mentwas externally calibrated before the analysis over the
entire mass range of interest. The data were acquired in
the mass range of m/z 800–2000 using a spray voltage of
4.0 kV. N2was used as a nebulizing gas at 20 psi, and the
capillary temperature was maintained between 200 and
230 °C. Data were acquired and processed using Xcalibur
1.4 SR1 software (Thermo Finnigan, San Jose, CA). The
glycopeptide compositions were assigned using the high
resolution data together with GlycoPep DB as described
previously [31].
CID Experiments in HPLC/ESI-FTICR MS
All MS/MS data were acquired in the linear ion trap of
the hybrid LTQ-FTICR in a data-dependent scanning
fashion in the positive ion mode. Data-dependent
MS/MS data were acquired for the first three most
intense ions observed in full MS1 scan using a dynamic
exclusion window. To maximize the amount of data-
dependent MS/MS scans collected for the glycopeptide
ions observed in full MS1 scan data, three more scan
events were set with each subsequent scan event select-
ing the second, third, and fourth most intense ions from
MS1 data. If a neutral loss of a hexose or a HexNAc was
detected in these scans, an MS3 scan event was trig-
gered. Each selected precursor ion was activated for 30
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Activation amplitudes were in the range of 22%–25% as
defined by the instrument software.
Data Analysis
To interpret the high resolution data acquired from
HPLC/ESI-FTICR MS, several steps were undertaken.
The first step was to determine if the peaks observed in
MS1 were glycopeptides or not. To verify this, the lower
mass range region of MS/MS data of those peaks were
examined for the presence of glycan characteristic prod-
uct ions like m/z 528 [HexNAc  2HexH], m/z 690
[HexNAc  3Hex  H], m/z 893 [2HexNAc 
3HexH], orm/z 657 [HexNAcHex Sialic Acid
H]. If any of these ions was observed, the next step
was to input the MS/MS peak list of the glycopeptides
in question into our newly developed web-based tool,
GlycoPep ID. A complete description of how this tool
operates was provided previously [32]. Briefly, GlycoPep ID
uses characteristic fragment ions, such as 0,2X ion
[Peptide  83  H] or Y1 ion [Peptide  203  H]
,
observed in MS/MS to predict the potential peptide
portion of the glycopeptides in question. From HPLC/
ESI-MS/MS data in the positive ion mode, each of the
scan events provided a specific characteristic fragmen-
tation ion, Y1 glycosidic bond cleavage that occurs at the
inner core of N-acetyl glucosamine (HexNAc) attached to
the peptide, and this ion was automatically predicted
by GlycoPep ID, thus identifying the peptide portion of
the glycopeptide in question. The identified peptide
portion was then imported into GlycoPep DB, described
previously [31], which utilizes the high resolution MS1
peak list to generate all the plausible glycan composi-
tions attached to that specific peptide. All the glycopep-
tide compositions generated were then inspected man-
Figure 1. The protein sequence for CON-S gp
highlighted in red. The peptides boxed in gree
peptides present in this protein with no missed cleavually and verified using MS1 and MS/MS data. MS/MS
data were also used to confirm the assigned carbohy-
drate compositions.
For MALDI-TOF/TOF data analysis, MALDI-
MS/MS data obtained from each glycopeptide fraction
was first utilized to identify the 0,2X ion [Peptide 83
H], a characteristic product ion that is typically ob-
served in MALDI-MS/MS corresponding to the peptide
plus a portion of the innermost HexNAc residue, which
remains after the cross ring cleavage [33]. The identified
peptide portion for each fraction was then input into
GlycoPep DB and using the high resolution MS1 peak-
list of that fraction, all the plausible glycopeptide com-
positions could be identified. These glycopeptide com-
positions were then verified manually using MS1 and
MS/MS data.
Results and Discussion
The group M consensus HIV-1 envelope protein,
CON-S gp140CFI, is a very heavily N-glycosylated
protein with 31 potential glycosylation sites [29]. Figure
1 shows the CON-S gp140CFI protein sequence with
all the potential glycosylation sites highlighted in red.
The peptides boxed in green represent all the possible
tryptic peptides containing one or more potential gly-
cosylation sites produced from this protein, with no
missed cleavages. The glycosylation on this protein has
recently been described [28], and in that work, glyco-
sylation analysis was demonstrated to be an effective
technique in correlating glycosylation profiles with vac-
cine efficacy. The work presented here uses this same
protein in a case study detailing the relative merits of
off-line HPLC, followed by MALDI TOF/TOF MS and
on-line HPLC-ESI-LTQ-FTICR-MS for glycopeptide
analysis. The protein was subjected to typical sample
FI with all the 31 potential glycosylation sites
present all the potentially glycosylated tryptic140C
n reages.
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tic digest) and analyzed using two of the most powerful
MS techniques, HPLC/ESI-FTICR-MS and MALDI-
TOF/TOF.
Figure 2 illustrates the analytical protocol employed
in this study. After the glycoprotein was digested with
trypsin, the total digest was divided into two portions.
Each portion was subjected to either capillary HPLC/
ESI-FTICR MS or HPLC fractionation followed by
MALDI-TOF/TOF MS analysis. In addition, the recon-
stituted HPLC fractions collected for MALDI-TOF/TOF
analysis were also deglycosylated and reanalyzed by
MALDI-TOF/TOF MS. The glycosylation information
content (sequence coverage, number, and type of gly-
cans) obtained from each MS approach was compared
to determine the strengths and weaknesses of the two
methods.
Assigning Glycopeptide Compositions
One of the key challenges in glycopeptide-based MS
analysis is assigning compositions to the masses ob-
served in MS1 data with a high confidence level. This is
because it is often possible to assign different glycopep-
tide compositions to the same mass, even when mass
accuracy is less than 5 ppm [34]. The process used to
assign the glycopeptide masses is detailed in the data
analysis portion of the Experimental section. Briefly, the
steps include: (1) determining whether or not an MS
peak is a glycopeptide, by looking for “marker ions”
produced when the peak is subjected to MS/MS anal-
ysis; (2) determining the peptide composition of the
glycopeptide, using MS/MS data and our data analysis
tool, GlycoPep ID; (3) determining the remaining por-
tion of the glycopeptide (the glycan mass) by using the
high resolution mass data and our analysis tool, GlycoPep
DB; (4) confirming the composition with MS/MS data.Figure 2. Work flow to illustrate the protocol usedAt the onset of this project, it was not apparent which
instrument platform would provide more readily
interpretable data; thus, a comparison was under-
taken to determine whether HPLC/ESI-FTICR-MS or
MALDI-TOF/TOF-MS had advantages in terms of
providing the most confirmatory information about the
glycopeptide compositions assigned. Figure 3a and b
represent MS/MS data of an example glycopeptide,
acquired via CID in the HPLC/ESI-LTQ-FTICR and
MALDI-TOF/TOF MS platforms, respectively. This
glycopeptide demonstrates the relative merits of
MS/MS analysis from each technique in providing
high confidence assignments for the peptide and
glycan compositions.
MS/MS Data from HPLC/ESI-FTICR MS
Figure 3a illustrates MS/MS data acquired in the linear
ion trap of the LTQ-FTICR mass spectrometer. In this
figure, the precursor ion, m/z 1477.15, was first identi-
fied to be a glycopeptide based on the marker ions
identified in the MS/MS data as described in the
Experimental section. The glycan composition for this
ion is confirmed by product ions resulting from glyco-
sidic bond cleavage of this glycopeptide. The glycosidic
cleavages are indicated in Figure 3a, and they include
sequential losses of nine hexoses (mannose residues),
confirming the presence of Man9, a high-mannose type
of N-linked glycan. The glycosidic cleavage resulting
from a loss of a HexNAc is represented by a square in
Figure 3a. As indicated in this spectrum, the cleavage of
all the glycosidic bonds present in this glycopeptide are
observed up to the innermost N-acetyl-glucosamine
residue (HexNAc), which is attached to the peptide
moiety of the glycopeptide. This corresponds to the Y1
ion [Peptide 203H], or both [Peptide 203H]
and [Peptide  349  H], when core fucosylation isto analyze CON-S gp140CFI glycopeptides.
ame
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[35] and it is observed in all MS/MS data of the
glycopeptides subjected to ESI MS/MS experiments;
since the Y1 ion corresponds to the peptide attached to
the innermost N-acetyl glucosamine (HexNAc), sub-
tracting the mass of this sugar (203 Da) from the
observed mass of the Y1 ion provides the mass of the
glycosylated peptide moiety. The product ion corre-
sponding to the Y1 ion can be identified either manually
or by simply inputting the MS/MS peaklist for this
glycopeptide (m/z 1477.15) into GlycoPep ID, available
at http://hexose.chem.ku.edu/predictiontable2.php, which
automatically outputs the potential peptide and its
corresponding Y1 ion (see the Experimental section). In
this case, GlycoPep ID was used to identify the Y1 ion,
which was identified as m/z 1290.74 (singly charged)
andm/z 646.08 (doubly charged ion) and its correspond-
ing peptide moiety, SN453ITGLLLTR. Taken together,
the glycosidic cleavage product ions explicitly confirm
the glycan portion of this glycopeptide, and the Y1 ion
Figure 3. A representative example of MS/M
compositions. (a) ESI-MS/MS data for a doubly
MS/MS data of the singly charged form of the sverifies the peptide composition. However, there wereno other product ions resulting from cleavage along the
peptide backbone; thus, further confirmation of the
peptide sequence was not feasible.
MS/MS Data from MALDI-TOF/TOF MS
Figure 3b represents MS/MS data obtained from
MALDI-TOF/TOF of the same glycopeptide shown
in Figure 3a. As indicated in Figure 3b, fewer product
ions are observed, compared with the ones observed
in Figure 3a. These ions include two sets of product
ions at or near the innermost HexNAc residues. The
two sets of product ions represent the Y1 ion ([Pep-
tide  203  H]) and the 0,2X ion ([Peptide  83 
H]) [35]. These pairs of ions were always observed
in all glycopeptides subjected to MALDI-MS/MS
experiments regardless of the type of N-linked gly-
cans (high-mannose, complex, or hybrid) present.
Like in MS/MS on the linear ion trap, when core
fucosylation is present, the Y1 ion, corresponding to
ata used to confirm the assigned glycopeptide
ed glycopeptide ion at m/z 1477.15. (b) MALDI-
glycopeptide (m/z 2952.55) as in (a).S d
charg[Peptide  349  H], is observed, along with the 0,2X
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0,2X ions are observed at m/z
1290.9 and 1170.8, respectively. Besides these two
product ions, there were no other glycan related
cleavage ions observed in the MALDI MS/MS exper-
iments [33]. This is because, unlike the low-energy
CID in the linear ion trap, MALDI-MS/MS is a
high-energy process that yields predominantly frag-
mentation ions originating from peptide bond cleav-
ages [27]. As a result, MS/MS of the glycopeptide at
m/z 2952.55 yields several y and b ions resulting from
peptide bond cleavage. Thus, this technique provides
detailed sequence and site attachment data for the
glycosylated peptide but provides minimal informa-
tion about the glycan moiety.
Overall, MS/MS acquired from the two high resolution
MS techniques, HPLC/ESI-LTQ-FTICR and MALDI-
TOF/TOF, provided confirmatory information in that in
both methods, the Y1 ion was always observed. This ion
was used as a characteristic ion to identify the peptide
moiety of the glycopeptide in question. The remaining
mass of the glycopeptide after subtracting the mass of the
Y1 ion can be used to indirectly determine the glycan
moiety for that glycopeptide. In MS/MS in the linear ion
trap, the characteristic Y1 ion was always observed as the
base peak for glycopeptides containing high-mannose
glycan compositions, but was not the base peak for
glycopeptides containing complex or hybrid glycans. This
is probably because loss of fucose and loss of 1-4 linked
N-acetylhexosamines (HexNAc) are both facile cleavages,
compared with glycosidic cleavages of high-mannose gly-
cans; therefore, glycosidic cleavages are often observed as
the base peak in MS/MS analysis of glycopeptides con-
taining hybrid and complex glycans. An example of
MS/MS data of a complex glycopeptide is shown in
Supplemental Figure 1.
In MALDI-MS/MS, in addition to the Y1 ion, the
0,2X
ion was also always observed, and either of these two ions
formed the base peak. It is worth noting that although
these ions identify the peptide moiety of the glycopeptide
in question, by providing the mass of the peptide, degly-
cosylation experiments generally identified the same pep-
tides as identified by the Y1 ion and the
0,2X ions. This
increased the confidence level of the identified peptides
from both ESI- and MALDI-MS/MS data. Furthermore,
for smaller mass ions (m/z 5000) and strongly ionizing
peptides, like arginine-containing tryptic peptides, the
peptide sequence could easily be obtained from MALDI
MS/MS data without deglycosylation. Therefore,
MALDI-TOF/TOF provided a higher confidence level for
identifying the peptide moiety than the HPLC/ESI-
FTICR-MS data. However, in terms of the glycan moiety
identified by both MS/MS techniques, HPLC/ESI-FTICR
provided a higher confidence level than MALDI-TOF/
TOF. When the two MS techniques are used together,
extensive information can be obtained about both the
peptide sequence and themonosaccharide units contained
in the glycan.Number of Glycoforms Identified
Table 1 shows the number of glycoforms identified at
each glycosylation site, detected from both HPLC/ESI-
FTICR and MALDI-TOF/TOF MS. This list is reflective
of the number of unique glycan compositions present at
each site only, as no attempt was made to infer glycan
structures or resolve isomers. The confidence level in
these glycan assignments is high, as the monosaccha-
ride units can usually be verified in the ESI-MS/MS
data, as described above. A complete list of all the
assigned glycan compositions can be found in Supple-
mental Table 1. The purpose of this table is to show
which glycopeptides were identified in MALDI-TOF/
TOF versus ESI-LTQ-FT MS analyses. From Table 1, it is
quite evident that the number of glycans obtained from
each glycosylation site differed greatly between the two
instruments. For instance, from HPLC/ESI-FTICR MS
data in Table 1, we identified 27 different glycan com-
positions attached to EANTTLFCASDAK peptide whereas,
from the same glycosylation site, only four glycan
compositions were identified using MALDI-TOF/TOF
MS. However, when another glycosylation site is exam-
ined, for example, from the peptide LREHFNN361K/
EHFNN361K, 35 different glycan compositions attached
to this site were identified using MALDI-TOF/TOF
(Table 1) whereas, from HPLC/ESI-FTICR MS, only
eight different glycan compositions were identified
from the same site (Table 1). As a result, the number of
glycan compositions identified varied from one glyco-
sylation site to the other between the two instruments.
Figure 4 shows a Venn diagram that demonstrates
glycan population coverage for MALDI-TOF/TOF and
HPLC/ESI-FTICRMS. As indicated in this figure, about
130 unique glycan compositions were identified using
each of the two MS techniques alone. About 90 identical
glycan compositions were identified by both methods.
Overall, 350 different glycan compositions were iden-
tified from all detected glycosylation sites by using
HPLC/ESI-FTICR and MALDI-TOF/TOF MS, and this
provided the best profile for the glycan population
present in CON-S gp140CFI.
Identification of the Most Abundant Type of
N-Linked Glycan Present
Table 1 also shows the most abundant type of N-linked
glycans identified from each glycosylation site using
both HPLC/ESI-FTICR MS and MALDI-TOF/TOF MS.
(Isomeric structures of the ones shown in Table 1 are
also possible). All three types of N-linked glycans,
high-mannose, hybrid, and complex type, were de-
tected from all the identified glycosylation sites; see
Supplemental Table 1. Although the number of glycans
detected at each site using the two methods differed, in
most cases they both provided similar results about the
most abundant glycan species present at each site. For
example, the total number of glycans found attached to
EHFNN361K/LREHFNN361K using MALDI-TOF/TOF
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Identified peptide
LC-ESI-FTICR-MS HPLC/MALDI-TOF/TOF
No of
glycans
Most abundant
structure m/z
No of
glycans
Most abundant
structure m/z
FNGTGPCK/CNDKKFNGTGPCK 4 1373.0222 (2) 12 3373.3042 (1)
EHFNNK/ LREHFNNK 8 1327.0049 (2) 35 2922.1624 (1)
QAHCNISGTK 5 1490.5868 (2) 6 2315.0049 (1)
SENITNNAK 11 1428.0684 (2) 1 2206.8865 (1)
NNNNTNDTITLPCR 27 1206.8378 (2) 23 3294.3725 (1)
DGGNNNTNETEIFRPGGGDMR 20 1300.2075 (3) 45 3898.6094 (1)
LDVVPIDDNNNNSSNYR 20 1199.5139 (3) 32 3596.5557 (1)
NCSFNITTEIR 32 1610.1519 (2) 26 3219.3145 (1)
SNITGLLLTR 21 1476.6450 (2) 12 2952.2661 (1)
WNKTLQQVAKK/WNK 2 1156.4409 (2) — — —
EANTTLFCASDAK 27 1646.6523 (2) 4 N/A —
LINCNTSAITQACPK 24 1778.2159 (2) 3 N/A -
AYDTEVHNVWATHACVPTDPN
PQEIVLENVTENFNMWK
14 1584.1990 (4) — — —
TIIVQLNESVEINCTRPNNNTR — — — 7 3639.7512 (1)
NVSTVQCTHGIKPVVSTQLLLN
GSLAEEEIIIR
— — — 9 5483.6548 (1)N/A, Not Applicable, glycopeptide peaks were very low in abundance making it impossible to identify the most abundant type of glycoform present.
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were detected. However, regardless of the significant
difference in number of glycans detected, the same
glycan structure ([Hex9HexNAc2]) was identified as the
most abundant species in both cases. Additionally,
seven of the nine glycosylated tryptic peptides identi-
fied by both MS methods produced the exact same
glycan composition as the most abundant species. The
remaining two glycosylated tryptic peptides both con-
tained high-mannose glycans, although the exact com-
position varied slightly between the two instruments
(see Table 1). From this table, it can also be seen that out
of all the glycosylation sites detected by both methods,
about 80% of them contained high-mannose N-linked
Figure 4. Venn diagram indicating the number of glycans de-
tected by either high resolution HPLC/ESI-FTICR-MS, MALDI-
TOF/TOF MS, or both.
Table 2. Glycosylation sites coverage from high-resolution MS
Tryptic peptides identified by HPLC/ESI-FTICR and MALDI-TOF
FN237GTGPCK/CNDKKFN237GTGPCK
EHFNN361K/ LREHFNN361K
QAHCN337ISGTK
SEN280ITNNAK
NNN413NTN416DTITLPCR
DGGNN466NTN469ETEIFRPGGGDMR
LDVVPIDDNNN190N191SSNYR
N155CSFN159ITTEIR
SN453ITGLLLTR
bEAN48TTLFCASDAK
bLINCN201TSAITQACPK
Unique tryptic peptides detected only in HPLC/ESI-FTICR MS
WN344KTLQQVAKK/ WN344K
AYDTEVHNVWATHACVPTDPNPQEIVLEN87VTENFNMWK
EINN643YTDIIYSLIEESQNQQEK
Unique peptides detected only in MALDI-TOF/TOF MS
TIIVQLN293ESVEIN299CTRPNN305NTR
N245VSTVQCTHGIKPVVSTQLLLN266GSLAEEEIIIR
DQQLEIWDN631MTWMEWER
Tryptic peptides undetected by both high resolution methods
LTPLCVTLN129CTNVN135VTN138TTN141NTEEK
GEFFYCN391TSGLFN397STWIGN403GTK
aFor peptides with more than one potential glycosylation site, the site o
resulting peptides. Experimental details are described in reference [28].
bPeptide sequences detected in low abundance in MALDI-TOF/TOF; verifiedglycans as the most abundant species. As a result, it can
be inferred that CON-S gp140CFI has a high degree of
high-mannose N-linked glycan structures.
Glycosylation Site Coverage
Theoretically, digestion of CON-S gp140CFI with
trypsin would produce a total of 19 unique tryptic
peptides containing one or more potential glycosylation
site(s) (assuming no missed cleavages), which would
account for the 31 potential glycosylation sites present
in this protein. To determine if any of the two MS
techniques could identify all the 31 potential glycosyl-
ation sites (19 tryptic peptides), we examined the num-
ber of tryptic peptides and their corresponding number
of glycosylation sites detected by each MS technique
and then compared the results.
Table 2 shows the glycosylated tryptic peptides and
the corresponding number of peptides detected from
both MS techniques. As shown in this table, from
HPLC/ESI-FTICR MS, a total of 14/19 tryptic peptides
each containing one or more potential glycosylation
sites were detected, which accounted for 18/31 poten-
tial glycosylation sites present in this protein. Figure 5a
is a representative example of MS1 data containing
glycoforms from two co-eluting tryptic peptides ob-
tained from HPLC/ESI-FTICR MS. As can be seen from
this figure, each tryptic peptide contained various gly-
coforms. A complete list of glycoforms from each of
these tryptic peptides can be found in Supplemental
Table 1.
Potential sites/occupied sitesa
MS
1
1
1
1
2/(1 and 2)
2/(1 and 2)
2/1
2/(1 and 2)
1
1
1
1
1
1
3/(1 and 2)
2/(1 and 2)
1
4/(2 and 3)
3/(2 and 3)
ncy was determined by deglycosylation with PNGase F and MS/MS on/TOF
ccupaby deglycosylation with PNGase F and MS/MS on resulting peptides.
ks as
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in parallel. The first analysis was performed by subject-
ing each of the reconstituted HPLC fractions to MALDI-
TOF/TOF analysis. Figure 5b illustrates an example of
MS1 data from MALDI-TOF/TOF; it contains the same
tryptic peptide as that shown in Figure 5a, from the
HPLC/ESI-FTICR MS data. The compositions of the
glycoforms shown in this figure can be found in Sup-
plemental Table 1.
In the second analysis, PNGase F was used to
deglycosylate each of the reconstituted HPLC frac-
tions analyzed in the first experiment. This enzyme
releases N-linked glycans from the protein, convert-
ing the asparagine residues (N) from which the
glycans are removed into aspartic acid (D). As a
result, a mass shift of 1 Da is expected to occur for
every utilized glycosylation site that is deglycosy-
lated [36]. This experiment was used to determine
glycosylation site occupancy [28] (reported in Table
2) and also to confirm glycopeptides whose abun-
dance was low in the high resolution MALDI-TOF/
TOF data. For instance, glycosylated tryptic peptides
LINCN201TSAITQACPK and EAN48TTLFCASDAK
were detected in low abundance in MALDI-TOF/
TOF in the first analysis, making it difficult to verify
them using MALDI-MS/MS before deglycosylation.
However, after deglycosylation (second analysis),
Figure 5. Representative examples of MS data
gp140CFI acquired on ESI-FTICR-MS and MAL
mass spectrum for the similar glycopeptide peathese tryptic peptides could be confirmed; moreimportantly, new tryptic peptides were also detected,
such as the two tryptic peptides shown in Table 2c,
LTPLCVTLN129CTNVN135VTN138TTN141NTEEK and
GEFFYCN391TSGLN397STWIG N403GTK, which con-
tain four and three potential glycosylation sites, re-
spectively. These tryptic peptides were also not de-
tected in HPLC/ESI-FTICR MS, probably because of
their high masses, when glycosylated.
Another issue with these two peptides that hinders
their ionization by MALDI-TOF/TOF is that they are
terminated in lysine. The lysine-containing tryptic pep-
tides are known to ionize less efficiently during MALDI
analysis than tryptic peptides containing arginine resi-
dues [37], and their ionization efficiency is even more
compromised since they are multiply glycosylated (and
thus large and heterogeneous). Furthermore, with the
high resolution of MALDI-TOF/TOF in the reflectron
mode, sensitivity for higher masses is lower than for
smaller masses, making it more difficult to detect these
tryptic glycopeptides in the first MALDI-TOF/TOF MS
analysis. As a result, it is possible to observe these
multiply glycosylated tryptic peptides after deglycosy-
lation (second analysis) but not when glycosylated (first
analysis). Overall, from MALDI-TOF/TOF analyses, a
total of 14/19 potentially glycosylated tryptic peptides,
corresponding to 21/31 potential glycosylation sites,
aining the same glycopeptide peaks for CON-S
OF/TOF-MS. (a) MS data from ESI, (b) MALDI
in (a).cont
DI-Twere identified.
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techniques may be inadequate in detecting all the
potential glycosylation sites present in a heavily glyco-
sylated protein like CON-S gp140CFI, a comparison
was performed to determine if there was any benefit
derived from combining the two high resolution MS
techniques in terms of the number of glycosylation sites
detected. A closer look at these results obtained from
both techniques revealed that only 11/19 potentially
glycosylated tryptic peptides, accounting for 15/31 po-
tential glycosylation sites, were identified from both
methods (see Table 2a). The remaining three and six
glycosylation sites were uniquely identified from either
high resolution HPLC/ESI-FTICR or MALDI-TOF/
TOF MS, respectively, and are listed in Table 2b. When
the numbers of glycosylation sites identified from the two
MS techniques are combined, 17/19 tryptic peptides
bearing one or more glycosylation sites are identified,
resulting in a total of 24 of the 31 potential glycosylation
sites. This coverage is higher than the 18 or 21 glyco-
sylation sites obtained from either HPLC/ESI-FTICR or
MALDI-TOF/TOF MS alone, thus increasing the prob-
ability of detecting as many potential glycosylation sites
as possible. Approximately 80% glycosylation coverage
was obtained when the two high resolution MS tech-
niques were used together.
In cases where full coverage of all glycosylation sites
is desired, lower resolution MS techniques like MALDI
MS analysis in the linear mode can be employed. This is
because at lower resolution, sensitivity is not as com-
promised as in high resolution analyses. However, the
low resolution analysis results in glycopeptides mass
assignments of lower confidence levels since the assign-
ments are based on average masses rather than mo-
noisotopic masses. Furthermore, the assigned glycopep-
tide compositions cannot be confirmed since MS/MS
capabilities are not available in the linear MALDI MS
mode. However, sometimes full coverage is the ulti-
mate goal, and low resolution MALDI-MS methods
were necessary to afford 100% coverage in this case.
Conclusions
This study demonstrates the use of two high resolution
MS techniques; MALDI-TOF/TOF and HPLC/ESI-
FTICR MS, to provide glycosylation information of a
highly glycosylated protein, CON-S gp140CFI. CID
experiments acquired on both instruments indicated
that ESI-MS/MS in a linear ion trap provided the most
complete information set for confirming the glycan
moieties present, including the acidic monosaccharide
units, while MS/MS on a MALDI-TOF/TOF provided
higher confidence assignments for confirming the pep-
tide portion of the same glycopeptide. When used
together, the two instruments provided a high degree of
information about the glycopeptides, affording high
confidence assignments. From the high resolution data,
14/19 tryptic peptides were obtained from each MS
technique accounting for 18/31 and 21/31 potentialglycosylation sites in this protein from HPLC/ESI-
FTICR and MALDI-TOF/TOF, respectively. When the
two instruments were used to complement each other,
24/31 tryptic peptides accounting for about 80% glyco-
sylation sites coverage was obtained, providing the best
glycosylation site coverage. However, to achieve 100%
glycosylation coverage, deglycosylation experiments
and lower resolution MALDI MS were required.
In terms of glycosylation data, different populations
of N-linked glycans comprising a wide range of high-
mannose, hybrid, and complex type N-linked glycans
were identified and characterized in a glycosylation
site-specific manner. Overall, the high-mannose glycans
were identified as the most abundant glycoforms from
both MS techniques. Approximately 350 glycopeptide
compositions were identified, when data from the two
techniques were combined. The information presented
in this study provides other researchers with useful
insight about what MS methods are most appropriate
for glycopeptide analysis, and how those methods can
be used synergistically to provide optimal glycosylation
coverage and high confidence assignments.
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